Argos Therapeutics announced that it has initiated dosing of patients in a Phase 1 clinical trial of its monoclonal antibody-based therapy, AGS-009, for the treatment of systemic lupus erythematosus (SLE). AGS-009 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with the ability to bind and neutralize human interferon alpha (IFN-alpha)...

More...